Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 17/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9753880 | 0.92 | MME (0.63) | MMECTSLCTSBCTSS | |
| SCHEMBL9753887 | 0.92 | MME (0.63) | MMECTSLCTSBCTSS | |
| SCHEMBL9753884 | 0.92 | MME (0.63) | MMECTSLCTSBCTSS | |
| SCHEMBL7450171 | 0.88 | MME (0.67) | MME | |
| SCHEMBL5924842 | 0.83 | MME (0.44) | MMECTSLCTSBCTSSALDH1A1 | |
| SCHEMBL9753583 | 0.83 | MME (0.44) | MMECTSLCTSBCTSSALDH1A1 | |
| SCHEMBL5924893 | 0.80 | MME (0.79) | MME | |
| SCHEMBL5925045 | 0.80 | MME (0.79) | MME | |
| SCHEMBL5925066 | 0.80 | MME (0.79) | MME | |
| SCHEMBL6429717 | 0.78 | MME (0.46) | MMECTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1438991-A | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER CIMITED (US) | 2003-08-27 | — | — | CN | disclosed |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER, INC. | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | ENGASE, ENPEP, CPN1 | MME 7/4885CTSL 154/4885CTSB 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.